BeStock  
Stocks › Biotechnology › AVLN

Avalyn Pharma AVLN

US equityMarket cap rank #3150Biotechnology
$25.53 +$0.10 (+0.39%)
Market closed · Oct 8, 7:00 am ET · Last extended-hours $25.53 0.00%
Open$25.30
Prev close$25.43
Day range$25.26 – $26.31
Volume202.9K
Market cap$1.13B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership108.9%+2.95 pts vs. prior quarter
Institutions holding117+5 vs. prior quarter
Insider trades (recent)16 buys / 0 sellsNet buying
Short interest4.72% of floatDays to cover 9.6 · as of 15 Sep 2026
Short-sale volume share29.6%5-day average of daily volume

Short-sale volume as % of daily volume

18%29%40%50%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$420.5K (13 inflow days, 7 outflow days).

Net flow by order size, last 20 sessions

+$54.2KSuper+$366.3KBig+$58.2KMid+$1.6MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 37.8% of shares outstanding.

Largest holders

  • Novo Holdings A/S8.76%
  • FMR8.01%
  • T. Rowe Price Group, Inc.7.53%
  • SR One Capital Management, LP7.46%
  • Perceptive Advisors LLC6.03%
  • Montanova Capital, LLC5.65%
  • F Prime, Inc.5.15%
  • Impresa Management LLC5.15%

By investor type

  • VC/PE Fund50.36%
  • Mutual Fund37.90%
  • Hedge Fund19.03%
  • Public Company0.81%
  • Sovereign Wealth Fund0.62%
  • Insurance Company0.05%
  • Private Company0.04%
  • Government Pension Fund0.03%

Reported short interest has fallen from 4.88% to 4.72% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Novo Holdings A/S VC/PE Fund 2026/Q3 +3,883,289 8.8%
FMR Mutual Fund 2026/Q3 +3,550,724 8.0%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +3,337,976 7.5%
SR One Capital Management, LP VC/PE Fund 2026/Q3 +3,308,649 7.5%
Perceptive Advisors LLC VC/PE Fund 2026/Q3 +2,675,296 6.0%
Montanova Capital, LLC Hedge Fund 2026/Q3 +2,503,109 5.6%
Impresa Management LLC VC/PE Fund 2026/Q3 +2,284,535 5.2%
NVP Associates, LLC VC/PE Fund 2026/Q3 +2,268,404 5.1%
Wellington Management Group Mutual Fund 2026/Q3 +2,201,986 5.0%
Catalio Capital Management, LP VC/PE Fund 2026/Q3 +1,675,830 3.8%
Eventide Asset Management, LLC Mutual Fund 2026/Q3 +1,375,486 3.1%
Bellevue Asset Management AG Mutual Fund 2026/Q3 +1,350,000 3.0%
BlackRock Mutual Fund 2026/Q3 +977,264 2.2%
Pivotal BioVenture Partners LLC VC/PE Fund 2026/Q3 +966,792 2.2%
Citadel Advisors LLC Hedge Fund 2026/Q3 +959,098 2.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
14 Sep 2026 Robert Meyer Director Other Derivative Acquisition +31,182 $34.28 31,182
30 Apr 2026 Wellington Management Group Derivative Exercise and Retained +1,275,486 – 1,275,486
30 Apr 2026 Novo Holdings A/S Private Acquisition +555,555 $18.00 3,883,289
30 Apr 2026 Novo Holdings A/S Derivative Exercise and Retained +3,327,734 – 3,883,289
30 Apr 2026 Impresa Management LLC Derivative Exercise and Retained +2,284,535 – 2,284,535
30 Apr 2026 SR One Capital Management, LP Private Acquisition +555,555 $18.00 3,308,649
30 Apr 2026 SR One Capital Management, LP Derivative Exercise and Retained +2,753,094 – 3,308,649
29 Apr 2026 Douglas Carlson CFO & Chief Business Officer Other Derivative Acquisition +211,975 $18.00 211,975
29 Apr 2026 Erin Lavelle Independent Director Other Derivative Acquisition +26,978 $18.00 26,978
28 Apr 2026 Novo Holdings A/S Initial Statement of Beneficial +0 – 652,649
28 Apr 2026 Douglas Carlson CFO & Chief Business Officer Initial Statement of Beneficial +0 – 354,074
28 Apr 2026 Heather Turner Independent Chairperson Other Derivative Acquisition +26,978 $18.00 26,978
28 Apr 2026 Heather Turner Independent Chairperson Initial Statement of Beneficial +0 – 64,919
28 Apr 2026 Lyn Baranowski Chief Executive Officer Other Derivative Acquisition +501,033 $18.00 501,033
28 Apr 2026 Lyn Baranowski Chief Executive Officer Initial Statement of Beneficial +0 – 1,499,081
28 Apr 2026 Kathryn Haviland Independent Director Other Derivative Acquisition +26,978 $18.00 26,978
28 Apr 2026 Kathryn Haviland Independent Director Initial Statement of Beneficial +0 – 43,928
28 Apr 2026 Jon Congleton Independent Director Other Derivative Acquisition +26,978 $18.00 26,978
28 Apr 2026 Jon Congleton Independent Director Initial Statement of Beneficial +0 – 43,928
28 Apr 2026 Erin Lavelle Independent Director Initial Statement of Beneficial +0 – 43,928

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 2,093,252 4.7% 9.6
31 Aug 2026 1,930,246 4.4% 11.3
14 Aug 2026 2,072,596 4.7% 10.9
31 Jul 2026 2,018,998 4.6% 9.4
15 Jul 2026 2,190,330 4.9% 5.6
30 Jun 2026 2,165,545 4.9% 3.1

Discussion

No comments yet — be the first to weigh in on AVLN.

Leave a comment

Scroll to Top